Compare Tango Therapeutics Inc. (TNGX) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Under Armour Inc Class A — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while Under Armour Inc Class A trades at $4.79 (market cap $2.08B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Under Armour Inc Class A for 99 Days on average.
| TNGX | UAA | |
|---|---|---|
Market Cap | $3.75B | $2.08B |
Volume | 9,619,106 | 7,012,020 |
Sector | Health | Consumer Cyclical |
52-Week High | $32.90 | $8.14 |
52-Week Low | $7.50 | $4.17 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $2.77B | $3.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Under Armour (UAA) trades at $4.90, down 0.61% amid ongoing revenue challenges but shows technical bullish signals. The company reported mixed Q2 2026 results with an earnings beat but faces declining revenues and negative net margins. Recent news highlights Under Armour's strategic focus on product simplification and international growth while navigating North American weakness. Technical indicators show bullish moving averages with RSI suggesting potential overbought conditions near-term.
The outlook remains challenging with revenue declines projected through 2026, though cost discipline supports margin recovery. Investment opportunity exists if the brand transformation succeeds, but risks include persistent demand weakness and competitive pressures. Analyst consensus is mixed with a $5.79 price target representing 18% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
